Loading...

Brainstorm Cell Therapeutics

DB:GHDN
Snowflake Description

Adequate balance sheet with moderate growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
GHDN
DB
$82M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. The last earnings update was 25 days ago. More info.


Add to Portfolio Compare Print
GHDN Share Price and Events
7 Day Returns
-2%
DB:GHDN
-2.7%
DE Biotechs
1.5%
DE Market
1 Year Returns
21.4%
DB:GHDN
-10.6%
DE Biotechs
-6.2%
DE Market
GHDN Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Brainstorm Cell Therapeutics (GHDN) -2% -4.8% 12.3% 21.4% - -
DE Biotechs -2.7% 3.8% -8.5% -10.6% 47.4% 10.3%
DE Market 1.5% 6% 8.5% -6.2% 10.7% 15.3%
1 Year Return vs Industry and Market
  • GHDN outperformed the Biotechs industry which returned -10.6% over the past year.
  • GHDN outperformed the Market in Germany which returned -6.2% over the past year.
Price Volatility
GHDN
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Brainstorm Cell Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Brainstorm Cell Therapeutics to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Brainstorm Cell Therapeutics.

DB:GHDN Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 3 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:GHDN
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.45
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.449 (1 + (1- 21%) (0%))
1.301
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.3
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.301 * 5.96%)
7.98%

Discounted Cash Flow Calculation for DB:GHDN using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Brainstorm Cell Therapeutics is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:GHDN DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 7.98%)
2019 -6.44 Analyst x1 -5.96
2020 -1.18 Analyst x1 -1.01
2021 60.46 Analyst x1 48.02
2022 141.22 Analyst x1 103.88
2023 217.40 Analyst x1 148.09
2024 257.17 Est @ 18.29% 162.23
2025 290.28 Est @ 12.87% 169.59
2026 316.64 Est @ 9.08% 171.31
2027 336.99 Est @ 6.42% 168.85
2028 352.37 Est @ 4.57% 163.51
Present value of next 10 years cash flows $1,128.50
DB:GHDN DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $352.37 × (1 + 0.23%) ÷ (7.98% – 0.23%)
$4,555.39
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $4,555.39 ÷ (1 + 7.98%)10
$2,113.75
DB:GHDN Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $1,128.50 + $2,113.75
$3,242.25
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $3,242.25 / 21.49
$150.87
DB:GHDN Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:GHDN represents 0.87184x of NasdaqCM:BCLI
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.87184x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 150.87 x 0.87184
€131.53
Value per share (EUR) From above. €131.53
Current discount Discount to share price of €3.31
= -1 x (€3.31 - €131.53) / €131.53
97.5%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Brainstorm Cell Therapeutics is available for.
Intrinsic value
>50%
Share price is €3.31 vs Future cash flow value of €131.53
Current Discount Checks
For Brainstorm Cell Therapeutics to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Brainstorm Cell Therapeutics's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Brainstorm Cell Therapeutics's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Brainstorm Cell Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Brainstorm Cell Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:GHDN PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-0.70
NasdaqCM:BCLI Share Price ** NasdaqCM (2019-04-23) in USD $3.8
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.6x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Brainstorm Cell Therapeutics.

DB:GHDN PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:BCLI Share Price ÷ EPS (both in USD)

= 3.8 ÷ -0.70

-5.45x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Brainstorm Cell Therapeutics is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Brainstorm Cell Therapeutics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Brainstorm Cell Therapeutics's expected growth come at a high price?
Raw Data
DB:GHDN PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -5.45x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
62.5%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 269 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Brainstorm Cell Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Brainstorm Cell Therapeutics's assets?
Raw Data
DB:GHDN PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $0.24
NasdaqCM:BCLI Share Price * NasdaqCM (2019-04-23) in USD $3.8
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:GHDN PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:BCLI Share Price ÷ Book Value per Share (both in USD)

= 3.8 ÷ 0.24

15.73x

* Primary Listing of Brainstorm Cell Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Brainstorm Cell Therapeutics is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Brainstorm Cell Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Brainstorm Cell Therapeutics has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Brainstorm Cell Therapeutics expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
62.5%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Brainstorm Cell Therapeutics expected to grow at an attractive rate?
  • Brainstorm Cell Therapeutics's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Brainstorm Cell Therapeutics's earnings growth is expected to exceed the Germany market average.
  • Unable to compare Brainstorm Cell Therapeutics's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:GHDN Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:GHDN Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts 62.5%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:GHDN Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:GHDN Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 641 182 2
2022-12-31 428 114 2
2021-12-31 145 42 3
2020-12-31 53 -4 3
2019-12-31 2 -11 3
DB:GHDN Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 -12 -14
2018-09-30 -12 -8
2018-06-30 -1 -8
2018-03-31 -3 -5
2017-12-31 -2 -5
2017-09-30 -1 -6
2017-06-30 -5 -5
2017-03-31 -5 -5
2016-12-31 -6 -5
2016-09-30 -6 -6
2016-06-30 -8 -7
2016-03-31 -8 -8

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Brainstorm Cell Therapeutics's earnings are expected to grow significantly at over 20% yearly.
  • Unable to determine if Brainstorm Cell Therapeutics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:GHDN Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from Brainstorm Cell Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:GHDN Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 4.38 5.19 3.56 2.00
2022-12-31 2.70 3.07 2.32 2.00
2021-12-31 0.99 1.08 0.89 2.00
2020-12-31 -0.15 -0.02 -0.27 2.00
2019-12-31 -0.45 -0.12 -0.66 3.00
DB:GHDN Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -0.70
2018-09-30 -0.42
2018-06-30 -0.39
2018-03-31 -0.29
2017-12-31 -0.26
2017-09-30 -0.31
2017-06-30 -0.27
2017-03-31 -0.27
2016-12-31 -0.27
2016-09-30 -0.31
2016-06-30 -0.36
2016-03-31 -0.43

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Brainstorm Cell Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Brainstorm Cell Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Brainstorm Cell Therapeutics has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Brainstorm Cell Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Brainstorm Cell Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Brainstorm Cell Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Brainstorm Cell Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Brainstorm Cell Therapeutics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Brainstorm Cell Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Brainstorm Cell Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:GHDN Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 -13.95 5.77 8.29
2018-09-30 -8.29 5.52 2.87
2018-06-30 -7.52 5.49 2.06
2018-03-31 -5.47 4.52 1.01
2017-12-31 -4.95 4.02 0.98
2017-09-30 -5.85 3.02 2.87
2017-06-30 -5.06 2.64 2.49
2017-03-31 -4.98 2.84 2.21
2016-12-31 -4.98 2.83 2.25
2016-09-30 -5.74 3.08 2.75
2016-06-30 -6.74 3.30 3.47
2016-03-31 -8.04 3.45 4.69
2015-12-31 -8.49 3.59 4.95
2015-09-30 -9.83 4.04 5.77
2015-06-30 -9.65 3.83 5.84
2015-03-31 -9.37 3.26 5.34
2014-12-31 -9.25 2.65 4.77
2014-09-30 -7.73 2.18 3.98
2014-06-30 -6.39 1.59 3.21
2014-03-31 -5.93 1.92 3.08
2013-12-31 -4.90 2.13 2.92
2013-09-30 -4.26 1.93 2.35
2013-06-30 -4.33 2.09 2.28
2013-03-31 -3.64 1.80 1.92
2012-12-31 -3.43 1.75 1.77
2012-09-30 -4.27 1.95 2.14
2012-06-30 -3.82 1.88 1.59

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Brainstorm Cell Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Brainstorm Cell Therapeutics has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Brainstorm Cell Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Brainstorm Cell Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Brainstorm Cell Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Brainstorm Cell Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Brainstorm Cell Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Brainstorm Cell Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Brainstorm Cell Therapeutics has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Brainstorm Cell Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Brainstorm Cell Therapeutics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Brainstorm Cell Therapeutics Company Filings, last reported 3 months ago.

DB:GHDN Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 5.02 0.00 7.06
2018-09-30 9.98 0.00 10.89
2018-06-30 12.87 0.00 17.44
2018-03-31 3.83 0.00 5.61
2017-12-31 5.88 0.00 7.76
2017-09-30 5.20 0.00 10.55
2017-06-30 7.29 0.00 6.72
2017-03-31 8.24 0.00 8.35
2016-12-31 9.90 0.00 9.99
2016-09-30 10.53 0.00 11.19
2016-06-30 11.87 0.00 11.48
2016-03-31 12.57 0.00 12.95
2015-12-31 14.13 0.00 15.96
2015-09-30 15.52 0.00 17.15
2015-06-30 17.84 0.00 19.70
2015-03-31 19.66 0.00 21.35
2014-12-31 6.68 0.00 8.54
2014-09-30 8.90 0.00 10.57
2014-06-30 10.60 0.00 11.33
2014-03-31 0.86 0.00 3.03
2013-12-31 2.74 0.00 3.50
2013-09-30 4.54 0.00 5.12
2013-06-30 2.36 0.00 2.54
2013-03-31 3.48 0.00 3.64
2012-12-31 3.98 0.00 4.09
2012-09-30 4.46 0.00 4.78
2012-06-30 0.25 0.00 0.84
  • Brainstorm Cell Therapeutics has no debt.
  • Brainstorm Cell Therapeutics has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Brainstorm Cell Therapeutics has less than a year of cash runway based on current free cash flow.
  • Brainstorm Cell Therapeutics has less than a year of cash runway if free cash flow continues to grow at historical rates of 0.8% each year.
X
Financial health checks
We assess Brainstorm Cell Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Brainstorm Cell Therapeutics has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Brainstorm Cell Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Brainstorm Cell Therapeutics dividends.
If you bought €2,000 of Brainstorm Cell Therapeutics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Brainstorm Cell Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Brainstorm Cell Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:GHDN Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:GHDN Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Brainstorm Cell Therapeutics has not reported any payouts.
  • Unable to verify if Brainstorm Cell Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Brainstorm Cell Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Brainstorm Cell Therapeutics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Brainstorm Cell Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Brainstorm Cell Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Brainstorm Cell Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Brainstorm Cell Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Chaim Lebovits
COMPENSATION $1,578,870
AGE 47
TENURE AS CEO 3.6 years
CEO Bio

Mr. Chaim Lebovits has been the Chief Executive Officer of Brainstorm Cell Therapeutics Inc. since September 22, 2015 and as its President since July 3, 2007. Mr. Lebovits serves as the Chief Executive Officer and President at ACC International Holdings Ltd. He has been the President of Dominion Minerals Corp. since July 30, 2008. He is the Founder of Rialto Energy (Côte d'Ivoire) Limited (AKA C & L Natural Resources Limited). He has been at the forefront of investments into mining and natural resources in emerging markets, especially the African region, for a number of years. He is active in gold exploration activities in Africaand oil and gas exploration in Israel. He served as the Principal Executive Officer at Brainstorm Cell Therapeutics Inc. since August 1, 2013. Mr. Lebovits led and negotiated many successful transactions with and on behalf of various African governments and international mining businesses. He has been a Director of Dominion Minerals Corp., since July 30, 2008. He served as a Director of Shemen Oil And Gas Resources Ltd. Mr. Lebovits served as a Non-Executive Director of Azonto Petroleum Ltd (formerly, Rialto Energy Limited) from July 24, 2010 to April 5, 2012.

CEO Compensation
  • Chaim's compensation has increased whilst company is loss making.
  • Chaim's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Brainstorm Cell Therapeutics management team in years:

1.4
Average Tenure
47
Average Age
  • The average tenure for the Brainstorm Cell Therapeutics management team is less than 2 years, this suggests a new team.
Management Team

Irit Arbel

TITLE
Founder & Chairperson
COMPENSATION
$66K
AGE
58

Chaim Lebovits

TITLE
President & CEO
COMPENSATION
$2M
AGE
47
TENURE
3.6 yrs

Eyal Rubin

TITLE
CFO & Treasurer
COMPENSATION
$351K
AGE
42
TENURE
1.4 yrs

Ralph Kern

TITLE
COO & Chief Medical Officer
COMPENSATION
$842K
AGE
60
TENURE
2.1 yrs

Uri Yablonka

TITLE
Executive VP
COMPENSATION
$35K
AGE
41
TENURE
2.1 yrs

Arturo Araya

TITLE
Chief Commercial Officer
COMPENSATION
$20K
AGE
47
TENURE
0.6 yrs

Yael Gothelf

TITLE
Vice President of Scientific & Regulatory Affairs

Joe Petroziello

TITLE
Vice President of Scientific & Corporate Communications
TENURE
0.8 yrs

Daniel Offen

TITLE
Chief Scientific Advisor

Susan Ward

TITLE
Head of Clinical Operations
TENURE
0.8 yrs
Board of Directors Tenure

Average tenure and age of the Brainstorm Cell Therapeutics board of directors in years:

7.9
Average Tenure
65.5
Average Age
  • The tenure for the Brainstorm Cell Therapeutics board of directors is about average.
Board of Directors

Uri Yablonka

TITLE
Executive VP
COMPENSATION
$35K
AGE
41
TENURE
4.8 yrs

Malcolm Taub

TITLE
Director
COMPENSATION
$37K
AGE
72
TENURE
10.1 yrs

Irit Arbel

TITLE
Founder & Chairperson
COMPENSATION
$66K
AGE
58
TENURE
5 yrs

Jerold Chun

TITLE
Chairman of Scientific Advisory Board
TENURE
1.1 yrs

Harvey Krueger

TITLE
Member of Business Advisory Board
AGE
88
TENURE
11.7 yrs

Jacob Frenkel

TITLE
Member of Business Advisory Board
AGE
75
TENURE
11.7 yrs

Rasheda Ali

TITLE
Member of Business Advisory Board
TENURE
11.5 yrs

Andrew Card

TITLE
Member of Business Advisory Board
AGE
70
TENURE
8.1 yrs

Chen Schor

TITLE
Director
COMPENSATION
$36K
AGE
46
TENURE
7.7 yrs

June Almenoff

TITLE
Director
COMPENSATION
$30K
AGE
61
TENURE
2.2 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
08. Jan 19 Buy June Almenoff Individual 04. Jan 19 04. Jan 19 1,475 €2.97 €4,386
X
Management checks
We assess Brainstorm Cell Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Brainstorm Cell Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes a patient’s own cells, which are engineered outside the body, to produce and secrete factors known to promote neuronal survival. It is developing NurOwn for various neurodegenerative diseases, including its lead indication, which is in Phase III clinical trial for the treatment of amyotrophic lateral sclerosis, as well as in preclinical trial for the treatment of multiple sclerosis, Parkinson’s disease, Huntington’s disease, and autism spectrum disorder. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in New York, New York.

Details
Name: Brainstorm Cell Therapeutics Inc.
GHDN
Exchange: DB
Founded: 2000
$72,877,237
21,490,610
Website: http://www.brainstorm-cell.com
Address: Brainstorm Cell Therapeutics Inc.
1745 Broadway,
17th Floor,
New York,
New York, 10019,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM BCLI Common Stock Nasdaq Capital Market US USD 14. May 2003
DB GHDN Common Stock Deutsche Boerse AG DE EUR 14. May 2003
Number of employees
Current staff
Staff numbers
31
Brainstorm Cell Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/23 20:32
End of day share price update: 2019/04/23 00:00
Last estimates confirmation: 2019/04/04
Last earnings filing: 2019/03/29
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.